|
|
||||||||
AJP - Endocrinology and Metabolism, Vol 267, Issue 3 E475-E484, Copyright © 1994 by American Physiological Society
ARTICLES |
N. G. Moore, G. G. Pegg and M. N. Sillence
Department of Chemistry, University of Central Queensland, Rockhampton, Australia.
It is reported that a long duration of action is required for beta 2-adrenoceptor agonists to evoke an anabolic response. In the present study, we compare the potency of clenbuterol with that of the new long-acting compound salmeterol, when given at equimolar doses to female Wistar rats by different routes of administration. Given orally for 10 days, salmeterol had no effect on growth at a dose of 120 micrograms/day, whereas at 2.4 mg/day the drug caused significant increases in body and carcass weight and in the mass of the mixed-fiber gastrocnemius/plantaris and tibialis anterior muscles, but there were no increases in the slow-twitch soleus muscles. A similar growth response was seen when clenbuterol was given orally at a dose of only 97 micrograms/day, with an additional response seen in soleus muscle at 1.9 mg/day. Thus clenbuterol was more potent than salmeterol when given by this route of administration. When the drugs were infused by osmotic minipump, both salmeterol (130 micrograms/day) and clenbuterol (100 micrograms/day) caused increases in body weight gain and in the weights of the mixed-fiber muscles, with the most dramatic effect of infusion being to greatly increase the anabolic effect of salmeterol in soleus muscle. A single intraperitoneal injection of salmeterol (53 micrograms) or clenbuterol (40 micrograms) caused a similar rapid increase in the concentration of adenosine 3',5'-cyclic monophosphate in gastrocnemius muscle. These results indicate that the potency of salmeterol in vivo is dependent on its route of administration and that slow-twitch muscles are less sensitive than mixed-fiber muscles to the anabolic effects of beta 2-adrenoceptor agonists.
This article has been cited by other articles:
![]() |
J. G. Ryall, J. D. Schertzer, T. M. Alabakis, S. M. Gehrig, D. R. Plant, and G. S. Lynch Intramuscular {beta}2-agonist administration enhances early regeneration and functional repair in rat skeletal muscle after myotoxic injury J Appl Physiol, July 1, 2008; 105(1): 165 - 172. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. G. Ryall, J. D. Schertzer, K. T. Murphy, A. M. Allen, and G. S. Lynch Chronic {beta}2-adrenoceptor stimulation impairs cardiac relaxation via reduced SR Ca2+-ATPase protein and activity Am J Physiol Heart Circ Physiol, June 1, 2008; 294(6): H2587 - H2595. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. S. Lynch and J. G. Ryall Role of {beta}-Adrenoceptor Signaling in Skeletal Muscle: Implications for Muscle Wasting and Disease Physiol Rev, April 1, 2008; 88(2): 729 - 767. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. G. Ryall, P. Gregorevic, D. R. Plant, M. N. Sillence, and G. S. Lynch beta 2-Agonist fenoterol has greater effects on contractile function of rat skeletal muscles than clenbuterol Am J Physiol Regulatory Integrative Comp Physiol, December 1, 2002; 283(6): R1386 - R1394. [Abstract] [Full Text] [PDF] |
||||
![]() |
P N R Dekhuijzen, H A Machiels, L M A Heunks, H F M van der Heijden, and R H H van Balkom Athletes and doping: effects of drugs on the respiratory system Thorax, November 1, 1999; 54(11): 1041 - 1046. [Full Text] |
||||
![]() |
Skeletal Muscle Dysfunction in Chronic Obstructive Pulmonary Disease . A Statement of the American Thoracic Society and European Respiratory Society Am. J. Respir. Crit. Care Med., April 1, 1999; 159(4): S2 - 40. [Full Text] [PDF] |
||||
![]() |
H. F. M. Van Der Heijden, P. N. R Dekhuijzen, H. Folgering, L. A. Ginsel, and C. L. A. Van Herwaarden Long-term effects of clenbuterol on diaphragm morphology and contractile properties in emphysematous hamsters J Appl Physiol, July 1, 1998; 85(1): 215 - 222. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |